大家在查： whupping MERLEAU Curbishley 西格蒙特•弗洛伊德拉·洛伊尔士敦 bolgia 希格门德弗洛伊德 , adjacent virtual concatenation

替尼

网络erlotinib; Sutent; Tykerb

替尼

替尼

erlotinib

摘要: 目的体外建立艾洛替尼(ERLOTINIB) 耐药的人肝癌细胞系HEPG2/ERLOTINIB, 鉴.. 全部>> 李家文档分享于 2013-03-01 0…

Sutent

【摘要】：索尼替尼(SUTENT)，系由美国辉瑞公司研发的抗癌新药，2006年1月在美国批准上市。它是一种具有高度选择性多 …

Tykerb

...sa) 和厄洛替尼(Tarceva)、乳癌的拉帕替尼 (Tykerb)、肝癌的拉索非明(Nexavar)、肾癌的舒尼替尼 (Sutent) 和依维莫司片(Aff…

1

Gefitinib failed to show superiority to placebo as second- or third-line treatment , but it has been shown to be non inferior to docetaxel .

吉非替尼在二线和三线治疗中与安慰剂相比无优势，但其作用不逊于多西他赛。

2

A recent phase III trial of the combination of gemcitabine with erlotinib was associated with a significant prolongation of survival .

一项最新的 III 期试验显示吉西他滨联合厄罗替尼布可以显著延长生存期。

3

Given the short period of follow-up in the research , the effect of the treatment on survival rates could not be corroborated.

研究跟踪报道接受舒尼替尼短期治疗后尚未发现能提高患者生存率。

4

When they tried Gleevec, known generically as imatinib , it had little effect on the cells .

当他们尝试着格列卫，通常被称依马替尼，它很少对细胞有作用。

5

Background Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than imatinib .

有研究表明与伊马替尼相比，尼罗替尼是一种更强效的 BCR-ABL 抑制剂。

6

How erlotinib exhibits its antineoplastic activity in vivo needs to be further elucidated.

厄洛替尼在体内是如何发挥抗肿瘤活性的机制需要进一步阐释。

7

9

One patient of each cohort required dose reduction of erlotinib , both due to skin rash .

2 组患者中均有 1 名患者因为皮疹需要减少厄罗替尼布剂量。

10

Preliminary results of phase III trial in pancreatic cancer revealed an improvement in survival with the addition of erlotinib .

三期临床试验的初步结果揭示了加用厄洛替尼之后患者生存率的提高。

13

Being female was also significantly associated with response to gefitinib .

病人是女性也与对吉非替尼有反应显著相关。

14

Erlotinib is also being evaluated in combination with capecitabine in patients who failed first-line therapy with gemcitabine .

厄罗替尼布联合卡培他滨同样用于一线药物吉西他滨治疗失败的患者。

15

The acute toxicity of gefitinib up to 500 mg in clinical studies has been low .

急性毒性吉非替尼多达 500 毫克的临床研究一直很低。

17

EGFR mutations in lung cancer : correlation with clinical response to gefitinib therapy .

肺癌中表皮生长因子受体突变：吉非替尼治疗的临床反应。

18

Axitinib is a pill taken twice daily , while Avastin is given periodically by intravenous infusion .

阿西替尼是一种片剂，每日服用两次，阿瓦斯丁是一种输液剂，需要定期进行静脉输液。

20

21

22

SUTENT is an anticancer drug that you take by mouth .

索坦（舒尼替尼）是一种口服抗癌药物。

23

The next step , says Jiang is finding a drug that blocks AHI-1, which could potentially be given in combination with imatinib in the future .

江表示，下一步是找一种阻滞 AHI-1 的药物，这种药物可能在将来与伊马替尼联用于治疗。

24

Sunitinib probably has a higher potency in terms of anti-angiogenesis but in some cases this may have a deleterious effect .

舒尼替尼可能有较强的抗血管生成能力，但在某些情况下，这可能有有害的影响。

26

The estimated overall survival rate for patients receiving Gleevec was 88% when considering deaths from all causes .

在进行死因分析时，接受伊马替尼治疗的患者的总体生存率为 88%。

27

Safety information from this study was consistent with previous Tykerb clinical studies in advanced breast cancer .

该研究发现拉帕替尼用于晚期乳腺癌患者的安全性与之前的临床研究一致。

28

Objective To evaluate the efficacy and safety of sunitinib in the treatment of metastatic renal clear cell carcinoma in our single center .

目的评价单中心舒尼替尼治疗转移性肾脏透明细胞癌的疗效和安全性。

29

30

热词推荐

大家在看